OCGN
Ocugen, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▲ Ocugen announced completion of patient enrollment in the Phase 3 liM…
- Mar 24 ▲ Ocugen announced positive 12-month Phase 2 data for OCU410, its gene…
- May 5 Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0…
- May 5 Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of…
- May 5 ▼ Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a…
- Jun 15 ▲ 1 insider buy $25.8K at $1.23
- Jul 13 ▲ Ocugen signed a binding term sheet with Roots Pharmaceutical to lice…
- Sep 1 ▲ Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial o…
- Sep 1 FDA: Ocugen Announces First Patient Dosed in Phase 3 Registrati…
- Sep 9 ▼ 1 insider sell $589.1K at $1.12
- Oct 9 ▼ 1 insider sell $499.7K at $0.9500
- Nov 10 Contract: Ocugen and Celairis Therapeutics Enter into Exclusive Lice…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $25.8K at an average $1.23. 1 insider sold $1.1M. Price is 37% below their cost.
- InstitutionsBULLISH
Q3 2026: 15 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +0.5% to 107.67M shares. 16.4 days to cover, ≈31.7% of shares.
- TrendDOWNTREND
16% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $9.8M |
| MARSHALL WACE, LLP | TRIM | $1.7M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $1.2M |
| MORGAN STANLEY | ADD | $626.6K |
| Quadrature Capital Ltd | DOUBLED | $615.5K |
| CITIGROUP INC | TRIM | $262.8K |
| JPMORGAN CHASE & CO | ADD | $248.3K |
| Creative Planning | DOUBLED | $238.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +1258%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| May 27, 2026 | Canaccord Genuity MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Musunuri Shankar Chief Executive Officer Oct 9, 2026 | SELL | $445.3K |
Musunuri Shankar Chief Executive Officer Oct 9, 2026 | SELL | $54.4K |
Musunuri Shankar Chief Executive Officer Sep 9, 2026 | SELL | $525.0K |
Musunuri Shankar Chief Executive Officer Sep 9, 2026 | SELL | $64.1K |
Johnson-Greene Treerita Essalima Chief Financial Officer Jun 15, 2026 | BUY | $25.8K |
Coleman Blaise Director Jun 11, 2026 | AWARD | 170,100 sh |
Zhang Junge Director Jun 11, 2026 | AWARD | 170,100 sh |
Castillo Kirsten Director Jun 11, 2026 | AWARD | 170,100 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.07 | -$0.08–-$0.06 | +12.5% | $1.1M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 6 press releases · 2 bullish · 0 bearish · 6 mixed · 9 neutral- NEUTRAL 8-KNov 10, 2026
Ocugen entered into an exclusive license agreement with Celairis Therapeutics for OCU400, a…
The deal provides non-dilutive funding and a path to commercial reach in Asia-Pacific, but all payments are contingent on clinical success and regulatory approval. Monitor the Phase 3 topline data…
- NEUTRAL PRESS RELEASENov 10, 2026
Ocugen granted Celairis exclusive rights to commercialize OCU400, its investigational gene therapy…
The deal provides modest near-term cash ($6.1M tied to near-term milestones) and validates OCU400's commercial potential outside the U.S. The key catalyst remains Phase 3 topline data in Q1 2027…
- NEUTRAL DEFA14ANov 6, 2026
Ocugen, Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on November 6…
The DEFA14A filing lacks any material disclosure about the subject of the proxy solicitation. Monitor for a definitive proxy statement or additional soliciting materials that may clarify the purpose…
- NEUTRAL DEFA14ANov 6, 2026
Ocugen filed a DEFA14A notice postponing its reconvened special meeting to December 22, 2026, to…
Monitor the December 22 special meeting outcome. If the proposal passes, the company will have capacity to issue up to 250 million additional shares, which could lead to future dilution. The…
All OCGN filing & press-release reports (23)
- 8-K reportNov 10, 2026
- PRESS-RELEASE reportNov 10, 2026
- DEFA14A reportNov 6, 2026
- DEFA14A reportNov 6, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportOct 15, 2026
- 8-K reportOct 14, 2026
- 144 reportOct 9, 2026
- PRESS-RELEASE reportSep 1, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportMar 24, 2026
- 8-K reportMar 4, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026
- PRESS-RELEASE reportMar 2, 2026